Lipella was granted FDA approval to evaluate LP-310 in patients with oral lichen planus (OLP). This phase 2A multi-center, dose-escalation clinical trial will assess the safety and efficacy of LP-310 in patients with symptomatic OLP. Lipella expects to begin patient recruitment for its Phase 2a studies in LP-310 in 2H 2024.

Oral Lichen Planus (OLP) is a chronic, inflammatory, T-cell-mediated, autoimmune oral mucosal disease. It is a painful condition with malignant potential, and complications include infections, scarring, stress and depression. OLP affects between one and four percent of the world’s population. Most currently available therapies are palliative rather than curative. There is currently no standard-of-care or FDA-approved therapy for OLP, a disease that affects over 6 million Americans.

For more information on the Lipella’s clinical trials call 412-894-1853 or email email this address.